Thursday | 26 April 2018
09.00 Welcome Session
Manuel Sobrinho-Simões, i3S/ Ipatimup & Mário Barbosa, i3S
SESSION 1: THE BASIS FOR IMMUNO-ONCOLOGY
Chairs: Rui Henrique and José Carlos Machado
9.15-9.45 Immunomodulation at the Tumor Microenvironment: basis and challenges
Maria José Oliveira, i3S / INEB
9.45-10.15 Neoantigen landscape dynamics during T cell therapy
Els Verdegaal, Leiden University Medical Centre
10.15-10.45 Coffee-break
10.45-11.15 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma
Shelly Kalaora, Weizmann Institute of Science
11.15-11:45 Selected talk | Different TLR signalling pathways induce macrophages or neutrophils with anti-tumour functions in vivo
Karine Serre, iMM – Instituto de Medicina Molecular – João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa
12.00-13.00 Lunch
13:00-15:00 Speed Talks
Chairs: Ana Sofia Ribeiro and Bruno Pereira
SESSION 2: RECENT ADVANCES IN IMMUNE CHECKPOINT BLOCKADE
Chairs: Paulo Cortes and André Albergaria
15.00-15.30 Neo-adjuvant therapy as pathway toward personalised immunotherapy
Christian Blank, Netherlands Cancer Institute
15.30-16.00 New strategies with immunotherapy for second-line non-small cell lung cancer
Manuel Cobo Dols, Hospital Regional Universitario Carlos Haya
16.00-16.30 Coffee-break
16.30-17.00 Biomarkers for Immunotherapy: the dark side
Fernando Schmitt, FMUP, i3S / Ipatimup
20.00 Meeting Dinner – Casa da Música
Friday | 27 April 2018
SESSION 3: IMMUNE CELL THERAPIES
Chairs: Nuno Alves and Júlio Oliveira
9.00-9.30 Delta One T cells: development of a novel immune cell therapy for cancer
Bruno Silva Santos, IMM
9.30-10.00 Expanding the T-cell therapy battlefield
Sébastien Wälchli, Oslo University Hospital-Radiumhospitalet
10.00-10.30 Coffee-break
10.30-11.00 Dendritic cell-based vaccination against cancer
Jolanda de Vries, Radboud Institute for Molecular Life Sciences (RIMLS); Radboud University Nijmegen Medical Centre
11.00-11.30 Selected talk | CD7-Edited T Cells Expressing a CD7-Specific Chimeric Antigen Receptor for the Therapy of Acute Myeloid Leukemia
Diogo Silva, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, Houston Methodist Hospital; Department of Bioengineering and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa
11.30-12.45 Speed talks
Chairs: Joana Figueiredo and João Vinagre
12.45-13.30 Lunch
13.30-14.30 Poster viewing
SESSION 4: NOVEL APPROACHES IN IMMUNO-ONCOLOGY
Chairs: Jorge Lima and José Dinis Silva
14.30-15.00 Provoke, Unleash, Prevent
Ezogelin Oflazoglu-Gruyters, MedImmune
15.00-15.30 Targeting natural immune regulation in oncology
Jocelyne Demengeot, Instituto Gulbenkian de Ciência
15.30-16.00 Redaporfin PDT combined with Anti-PD-1 treatment in melanoma mouse model: alterations in T-cell subsets
Carlos Palmeira, IPO-Porto
Adjourn
